Back to top
more

Smith & Nephew SNATS (SNN)

(Delayed Data from NYSE)

$35.50 USD

35.50
1,348,087

+0.02 (0.06%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $35.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MedTech Industry Outlook - October 2017

by Zacks Equity Research

The Trump administration has not come up with any concrete plan to replace the MedTech tax as of yet.

    Zacks Equity Research

    Graham-Cassidy Fail Shines Spotlight on 3 Top Dividend Stocks

    by Zacks Equity Research

    Zeroing in on dividend stocks with a solid Zacks Rank is a great way to increase the chances of beating volatile market conditions while ensuring a steady stream of cash flow. Here are three top picks in the MedTech space.

      Zacks Equity Research

      The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew

        Zacks Equity Research

        Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill

        by Zacks Equity Research

        The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.

          Zacks Equity Research

          Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy

          by Zacks Equity Research

          The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.

            Zacks Equity Research

            MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails

            by Zacks Equity Research

            Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.

              Swarup Gupta headshot

              5 British Stocks to Profit From a Weak Pound Sterling

              by Swarup Gupta

              Companies exporting products and services stand to benefit from a weaker pound.

                Zacks Equity Research

                3 MedTech Stocks Set to Rally in the Second Half

                by Zacks Equity Research

                The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.

                  Zacks Equity Research

                  Anika (ANIK) Grows in Orthopedic Medicines on Positive Data

                  by Zacks Equity Research

                  Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.

                    Zacks Equity Research

                    Medical Product Stocks Q1 Earnings Slated on May 5: VWR, SNN

                    by Zacks Equity Research

                    Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 5.

                      Zacks Equity Research

                      MedTech Industry Stock Outlook - March 2015

                      by Zacks Equity Research

                      Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.

                        Zacks Equity Research

                        MedTech Industry Stock Outlook - March 2015

                        by Zacks Equity Research

                        Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.

                          Zacks Equity Research

                          MedTech M&As Continue Regardless of Tax Scenarios

                          by Zacks Equity Research

                          MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.